# Orexo and SVF Vaccines Partner on mRNA Delivery Technology Companies will test AmorphOX® powder technology for stabilizing lipid nanoparticle mRNA vaccines. - **Source:** [News-Medical](https://www.news-medical.net) - **Published:** 2026-11-12 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/0c1f6712-6353-4f76-8f09-943bc4138e8d ## Strategic Research Collaboration Orexo AB and SVF Vaccines AB have officially entered a research collaboration agreement. The partnership aims to explore the potential of Orexo’s proprietary drug delivery platform, known as AmorphOX®. This joint effort focuses on the technical feasibility of applying powder-based formulations to advanced medical products within the current vaccine development landscape. ## Targeting mRNA Stability The primary objective of this research is to stabilize lipid nanoparticle encapsulated mRNA vaccines. Currently, mRNA-based therapeutics often require strict cold-chain logistics due to their inherent sensitivity to temperature fluctuations. By utilizing a powder-based approach, the companies hope to overcome these significant storage and distribution challenges for future vaccine candidates. ## AmorphOX® Technology Mechanism AmorphOX® is a proprietary powder-based drug delivery technology developed by Orexo. It is designed to enhance the stability and solubility of various pharmaceutical compounds. The technology works by creating an amorphous solid dispersion, which protects sensitive active ingredients from degradation while maintaining their biological efficacy during the shelf-life of the product. ## Lipid Nanoparticle Challenges Lipid nanoparticles are essential for delivering mRNA into human cells, yet they remain highly fragile structures. They are prone to aggregation and chemical breakdown when exposed to heat or improper handling. This research seeks to determine if Orexo's powder technology can effectively encapsulate these particles to preserve their structural integrity. ## Advancing Vaccine Logistics If successful, this collaboration could fundamentally change how mRNA vaccines are transported globally. Moving away from liquid-based, cold-chain dependent formulations to stable powder forms would simplify supply chain requirements. This transition would be particularly beneficial for reaching remote or resource-limited regions where maintaining consistent refrigeration is often a major hurdle. ## Industry Context of mRNA The mRNA platform gained global prominence during the recent pandemic, proving its speed and versatility in vaccine development. However, the industry continues to face hurdles regarding the long-term stability of these complex molecules. Researchers are actively seeking new delivery methods to ensure these treatments remain potent and accessible for broader populations. ## Developmental Research Phase The current collaboration is strictly focused on the research and investigation phase of the project. Both Orexo and SVF Vaccines have not disclosed specific timelines for clinical trials or commercialization. The initial work will likely involve rigorous laboratory testing to validate the compatibility of the AmorphOX® platform with mRNA materials. ## Future Implications for Healthcare This partnership represents a significant step toward making mRNA technology more robust and user-friendly. By integrating specialized drug delivery systems, the pharmaceutical industry aims to reduce costs and logistical complexities. The success of this research could pave the way for a new generation of more stable, easily distributable mRNA-based medical solutions. ## Sources covering this story - https://www.news-medical.net/news/20261112/Orexo-and-SVF-Vaccines-collaborate-to-explore-AmorphOXc2ae-formulation-of-LNP-mRNA-vaccines.aspx — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._